|
Getting your Trinity Audio player ready...
|
I debated writing this post because it borders on science, which is not usually my territory. But the question of PSP variants comes up constantly in support groups, and I thought it was worth making an effort to provide a basic guide in plain language, for people like me who are trying to make sense of a complicated picture without a medical degree. Sometimes even I can’t get away from the science. And in our shop of horrors that is PSP, knowledge is power, or at least a tiny bit of it.
Why should there be just one PSP when there can in fact be many different types of the same condition? To a layman, that actually makes complete sense. By its nature PSP is not fully understood, and it is an inherently atypical disease, so it stands to reason that it would show up differently in different people. Sadly, this probably makes finding a single treatment or cure harder. It is simply not one size fits all.
I am learning the science quickly and am by no means an expert, but the charts and descriptions below give a sense of just how much variation there is across the PSP family. PSP is a rare disease, affecting only around five or six people in every hundred thousand, yet it presents in remarkably different ways. The charts were made using AI and have been double-checked, but they are directional rather than definitive and should be read in that spirit.
Why this matters to me personally
Over the last few weeks I have had a series of worrying episodes: Bell’s Palsy, a suspected TIA (mini-stroke), oedema (swelling) in my hands and feet, and what appear to be seizures. It has been genuinely hard to know whether each of these warrants a trip to the emergency room or whether they are simply part of how PSP expresses itself in me. I spoke to a doctor today who agreed that these are judgement calls, and that we have probably been making the right ones so far.
What all PSP variants have in common
Before describing the individual types, it is worth understanding what unites them all. Every PSP variant shares the same underlying pathology: the abnormal build-up of a protein called 4-repeat tau in specific regions of the brain, confirmed only at autopsy. The tau progressively disrupts the circuits controlling movement, balance, eye movement, speech, and cognition. Which variant a person develops depends on the particular pattern of where that tau accumulates first and most strongly.
Tau is currently getting a great deal of attention in the research world, and not only because of PSP. It is also the core ingredient of Alzheimer’s disease, which means that the billions of dollars flowing into Alzheimer’s research are quietly also advancing our understanding of PSP. The two conditions are not the same, and the tau behaves differently in each, but the overlap in the underlying biology means that PSP patients have a quiet stake in every tau-related breakthrough, wherever it comes from.
Think of it like a fire breaking out in a large building. The fire itself, the tau, is the same in every case. But which rooms it reaches first, and in what order, determines what the damage looks like from the outside. And it is worth adding that many patients do not remain neatly within a single variant. Features often overlap and evolve over time.
The types
PSP-RS (Richardson syndrome, classic PSP): approximately 50 to 60 percent of cases. The most common form, characterised by early falls, balance problems, rigidity, and difficulty moving the eyes. It typically has the shortest path to loss of independence.
PSP-P (Parkinsonism variant): approximately 15 to 20 percent. Parkinson’s-like features dominate early with a slower overall course. It is the most common variant after RS and the one most frequently misdiagnosed as Parkinson’s disease.
CBS (Corticobasal syndrome): approximately 5 to 10 percent. Early executive dysfunction, behavioural change, and apathy. CBS is a clinical syndrome rather than a single disease, since the underlying pathology may be PSP, corticobasal degeneration, or Alzheimer’s disease. It is worth noting that many clinicians treat CBS as a separate diagnostic category in its own right rather than a PSP variant, and there is ongoing debate in the field about where it properly belongs. It appears here because PSP is one of its most common underlying causes, and because it features in the 2017 international PSP diagnostic criteria.
PSP-PGF (Progressive gait freezing): approximately 3 to 7 percent. Freezing of gait appears early while cognition is relatively preserved for longer.
PSP-SL (Speech and language variant): approximately 3 to 6 percent. Speech apraxia or language difficulties are the first signs, before more typical PSP features emerge.
PSP-OM (Oculomotor variant): approximately 3 to 6 percent. Eye movement problems are prominent early. It is included in the 2017 international diagnostic criteria, though less commonly used as a standalone clinical label.
PSP-F (Frontal and behavioural variant): approximately 2 to 6 percent. Personality and behavioural changes come first, sometimes resembling frontotemporal dementia, with physical symptoms arriving later.
PSP-PI (Postural instability variant): approximately 2 to 6 percent. Early balance problems and falls without prominent gaze palsy, which can make diagnosis more difficult.
PSP-C (Cerebellar variant): approximately 2 to 5 percent. Uncoordinated, clumsy movement dominates early, with cognitive changes typically appearing later. It is the rarest and most diagnostically elusive of the variants.
My own variant
In discussions with my neurologist, PSP-P is my most likely type, which fits with my earlier Parkinson’s diagnosis and my relatively slower cognitive decline. The better news is that PSP-P often allows a longer period of retained independence and cognitive function than some other variants. My main physical challenge is rigidity, particularly freezing, rather than the clumsy uncoordinated movement of the cerebellar variants. The hard reality is that it is still PSP. There is no cure, no disease-modifying treatment, and the prognosis remains serious, even if it is somewhat better than some of the faster-progressing sub-types.
Life expectancy: the broad picture
I want to handle this briefly and honestly. Median survival from symptom onset is generally around six to ten years, though there is wide individual variation and published figures tend to come from specialist clinic studies which may skew toward more severe cases. Variant matters: PSP-RS sits toward the shorter end, typically six to eight years, while PSP-P and PSP-PGF tend toward the longer end, often eight to twelve years or beyond. Data for rarer variants is limited due to small study sizes. Two things are worth saying plainly: these are medians, meaning half of people live longer than the figure quoted and half shorter, and the quality of care, the management of complications, and the strength of support around a person all influence the trajectory in ways that raw statistics cannot capture.
What to take from all of this
If you are reading this as a patient, a carer, or simply someone trying to understand what PSP actually is, I hope this helps. I wrote it because I needed it myself. I will be honest: I am not entirely sure how much knowing these facts changes anything on a day to day basis. But they are what the science says, and I think it matters, particularly for caregivers, to have at least a working familiarity with them. If nothing else, it may prove useful when you find yourself sitting in a medical meeting trying to decode the occasional gibberish that passes for plain English in those rooms. Understanding the language, even partially, means you can ask better questions, push back when something does not add up, and leave feeling less like a bystander in your own care.
One of the most disorienting things about a PSP diagnosis is that the disease refuses to behave consistently. You read something about PSP and half of it does not match your experience, or your loved one’s experience, and you wonder whether you have the right diagnosis at all. The answer, more often than not, is that you probably do. PSP simply looks different depending on which variant you have, and for many people it takes years, sometimes a decade, to get the right label, if it ever comes at all.
Knowing your variant, or at least having a working hypothesis about it, matters for several practical reasons. It shapes what symptoms to expect and in what order. It informs which clinical trials you might be eligible for, since researchers increasingly recruit by subtype rather than by PSP as a blanket category. It helps your care team focus their energy in the right places. And it helps you, as a patient or carer, to stop measuring yourself against the wrong benchmark.
PSP is rare, under-researched, and underfunded relative to the suffering it causes. But the science is moving, the diagnostic criteria are being refined, and the community of patients, carers, researchers, and clinicians who are paying attention is growing. Understanding the landscape, even imperfectly, is not a small thing. It is how we begin to navigate it with some degree of intention rather than simply being carried along by it.
That, at least, is why I am writing. And why I will keep writing.
Sources and further reading
The variant descriptions and prevalence figures in this post draw on the following:
Höglinger GU et al. Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria. Movement Disorders, 2017. The foundational paper establishing the current classification of PSP variants and the framework used in both charts above.
Respondek G et al. The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2014. The key early study mapping the clinical diversity of PSP subtypes in a large autopsy-confirmed cohort.
Williams DR et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy. Brain, 2005. The paper that first clearly distinguished PSP-RS from PSP-P as separate clinical entities.
Glasmacher SA et al. Survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017. The most comprehensive published synthesis of survival data across PSP subtypes.
Kukkle PL et al. Progressive supranuclear palsy: a global review. Movement Disorders Clinical Practice, 2025. A recent overview covering epidemiology, phenotypes, and geographic variation.
The charts in this post were generated using AI tools and reviewed against published sources. They are intended as illustrative rather than definitive, and the prevalence figures reflect ranges across studies rather than single authoritative estimates.
